Emerging Treatment Models in Rheumatology: Challenges for Osteoarthritis Trials

Arthritis and Rheumatology

Volumn 70, Issue 8, 2018, Pages 1175-1181

  Felson, David T ^a   Neogi, Tuhina ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE EXACERBATION; GENERAL CONDITION DETERIORATION; HUMAN; JOINT CAVITY; NOCICEPTIVE PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; REPLACEMENT ARTHROPLASTY; SIGNAL DETECTION; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; CLINICAL TRIAL (TOPIC); METHODOLOGY; RHEUMATOLOGY;

CLINICAL TRIALS AS TOPIC; HUMANS; OSTEOARTHRITIS; RESEARCH DESIGN; RHEUMATOLOGY;

EID: 85050607140     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40515     Document Type: Article

References (46)

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602
2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780–5
3. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40
4. Parkes MJ, Callaghan MJ, Tive L, Lunt M, Felson DT. Sensitivity to change of single versus composite measures of pain in knee osteoarthritis. J Rheumatol 2018. In press
5. Parkes MJ, Callaghan MJ, O'Neill TW, Forsythe LM, Lunt M, Felson DT. Sensitivity to change of patient-preference measures for pain in patients with knee osteoarthritis: data from two trials. Arthritis Care Res (Hoboken) 2016;68:1224–31
6. Lo GH, McAlindon TE, Hawker GA, Driban JB, Price LL, Song J, et al. Symptom assessment in knee osteoarthritis needs to account for physical activity level. Arthritis Rheumatol 2015;67:2897–904
7. Dworkin RH, Richlin DM, Handlin DS, Brand L. Predicting treatment response in depressed and non-depressed chronic pain patients. Pain 1986;24:343–53
8. Arendt-Nielsen L, Jiang GL, DeGryse R, Turkel CC. Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol 2017;46:303–16
9. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153:1193–8
10. Conaghan PG, DiFrancesco A, Swearingen CJ, Kennedy S, Simsek I, Tambiah J, et al. Reducing heterogeneity in OA clinical trials: data from a phase 2 study of SM04690, a novel, intra-articular, Wnt pathway inhibitor in knee osteoarthritis [abstract]. Arthritis Rheumatol 2017;69 Suppl 10. URL: http://acrabstracts.org/abstract/reducing-heterogeneity-in-oa-clinical-trials-data-from-a-phase-2-study-of-sm04690-a-novel-intra-articular-wnt-pathway-inhibitor-in-knee-osteoarthritis/
11. Juni P, Hari R, Rutjes AW, Fischer R, Silletta MG, Reichenbach S, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 2015:CD005328
12. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014:CD000957
13. Brandt KD, Mazzuca SA, Buckwalter KA. Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford) 2006;45:1389–94
14. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87–91
15. Verkleij SP, Luijsterburg PA, Bohnen AM, Koes BW, Bierma-Zeinstra SM. NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes. Osteoarthritis Cartilage 2011;19:921–9
16. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363:1521–31
17. Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage 2015;23 Suppl 1:S8–17
18. Osteoarthritis Research Society International. Osteoarthritis: a serious disease. URL: https://www.oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf
19. Guermazi A, Roemer FW, Felson DT, Brandt KD. Motion for debate: osteoarthritis clinical trials have not identified efficacious therapies because traditional imaging outcome measures are inadequate. Arthritis Rheum 2013;65:2748–58
20. Gale DR, Chaisson CE, Totterman SM, Schwartz RK, Gale ME, Felson D. Meniscal subluxation: association with osteoarthritis and joint space narrowing. Osteoarthritis Cartilage 1999;7:526–32
21. Hunter DJ, Zhang YQ, Tu X, Lavalley M, Niu JB, Amin S, et al. Change in joint space width: hyaline articular cartilage loss or alteration in meniscus? Arthritis Rheum 2006;54:2488–95
22. Segal NA, Frick E, Duryea J, Roemer F, Guermazi A, Nevitt MC, et al. Correlations of medial joint space width on fixed-flexed standing computed tomography and radiographs with cartilage and meniscal morphology on magnetic resonance imaging. Arthritis Care Res (Hoboken) 2016;68:1410–6
23. Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494–507
24. Hellio Le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013;72:187–95
25. White DK, Zhang Y, Niu J, Keysor JJ, Nevitt MC, Lewis CE, et al. Do worsening knee radiographs mean greater chances of severe functional limitation? Arthritis Care Res (Hoboken) 2010;62:1433–9
26. Fukui N, Yamane S, Ishida S, Tanaka K, Masuda R, Tanaka N, et al. Relationship between radiographic changes and symptoms or physical examination findings in subjects with symptomatic medial knee osteoarthritis: a three-year prospective study. BMC Musculoskelet Disord 2010;11:269
27. Oak SR, Ghodadra A, Winalski CS, Miniaci A, Jones MH. Radiographic joint space width is correlated with 4-year clinical outcomes in patients with knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2013;21:1185–90
28. Johnson SR, Archibald A, Davis AM, Badley E, Wright JG, Hawker GA. Is self-reported improvement in osteoarthritis pain and disability reflected in objective measures? J Rheumatol 2007;34:159–64
29. Thomas E, Peat G, Mallen C, Wood L, Lacey R, Duncan R, et al. Predicting the course of functional limitation among older adults with knee pain: do local signs, symptoms and radiographs add anything to general indicators? Ann Rheum Dis 2008;67:1390–8
30. Schnitzer TJ, Popovich JM, Andersson GB, Andriacchi TP. Effect of piroxicam on gait in patients with osteoarthritis of the knee. Arthritis Rheum 1993;36:1207–13
31. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage 2015;23 Suppl 1:S18–21
32. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989;2:519–22
33. Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009;68:938–47
34. Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014;66:1820–31
35. Felson DT, Niu J, Neogi T, Goggins J, Nevitt MC, Roemer F, et al. Synovitis and the risk of knee osteoarthritis: the MOST Study. Osteoarthritis Cartilage 2016;24:458–64
36. Felson DT, McLaughlin S, Goggins J, Lavalley MP, Gale ME, Totterman S, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139:330–6
37. O'Neill TW, Parkes MJ, Maricar N, Marjanovic EJ, Hodgson R, Gait AD, et al. Synovial tissue volume: a treatment target in knee osteoarthritis (OA). Ann Rheum Dis 2016;75:84–90
38. Zhang Y, Nevitt M, Niu J, Lewis C, Torner J, Guermazi A, et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum 2011;63:691–9
39. Callaghan MJ, Parkes MJ, Hutchinson CE, Gait AD, Forsythe LM, Marjanovic EJ, et al. A randomised trial of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions. Ann Rheum Dis 2015;74:1164–70
40. Laslett LL, Dore DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012;71:1322–8
41. Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs [review]. Arthritis Rheum 2005;52:3349–59
42. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494–502
43. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–1500
44. Pavord ID, Chanez P, Criner GJ, Kerstjens HA, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017;377:1613–29
45. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74
46. Radnovich R, Scott D, Patel AT, Olson R, Dasa V, Segal N, et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthritis Cartilage 2017;25:1247–56